Physician profile
Aaron C Mack
NPI 1225023047
$3,537.38
in general payments reported to CMS, 2019-2025
22 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $267 · 2021: $209 · 2022: $412 · 2023: $568 · 2024: $726 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $875.31 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Oyster Point Pharma, INC. | $360.03 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $358.68 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $317.55 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $241.47 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $221.65 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $138.39 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $131.18 | 2019 | |
| Thea Pharma INC. | $121.99 | 2022-2025 | Iyuzeh |
| Allergan, INC. | $118.23 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $101.88 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $96.89 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $62.19 | 2019-2021 | |
| New World Medical,INC. | $34.18 | 2023-2024 | Streamline, Ahmed Glaucoma Valve, Clearpath |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $25.00 | 2024 | Rayone Aspheric, Rayone Emv, Omidria |
| Biotissue Holdings INC. | $23.00 | 2025 | |
| Rxsight INC | $21.78 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Amgen INC. | $19.38 | 2025 | Tepezza |
| Sight Sciences, INC. | $18.03 | 2021 | |
| Ocular Therapeutix, INC. | $15.65 | 2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.